HemoGenyx utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by HemoGenyx Co-Founder Dr Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results. Hu-PHEC-based technology presents a number of important advantages compared to other existing and developing technologies. Most of these advantages are rooted … Continue reading Hu-PHEC